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Background: Reviewing clinical trial site performance identifies strategies to control outcomes. Performance across
5 geographical regions (36 sites across Asia, Australia, Europe, North America and Latin America) was investigated in
a study that randomised 322 HIV-infected individuals.
Methods: Regional performance was compared using descriptive analysis for time to site opening, recruitment,
quality of data and laboratory samples. Follow-up consisted of 10 visits (96 weeks), electronic data collection (EDC)
within 7 days of a visit and serious adverse events (SAEs) reported within 24 hours of site awareness.
Results: Median days to site opening was 250 (188 to 266), ranging from 177 (158 to 200) (Australia) to 265 (205 to
270) (Europe). Median days to ethics and regulatory approval was 182 (120 to 241) and 218 (182 to 341) days,
respectively. Within regions, time to approval ranged from 187 (91 to 205) days (Australia) to 276 (175 to 384) days
(Europe). Time to first randomisation ranged from 282 (250 to 313) days (Australia) to 426 (420 to 433) days (North
America).
Recruitment was lower than forecasted in Asia, Australia, Europe and North America at 89%, 77%, 91% and 43%,
respectively. The converse was true in Latin America where despite ethics, regulatory and contractual delays,
recruitment was 104% of predicted.
Median days to EDC was 7 (3 to 16), ranging from 3 (1 to 16) (Asia) to 13 (8 to 14) days (North America). Median
days for initial SAE submission to sponsor was 6 (2 to 20), ranging from 4 (2 to 18) (Latin America) to 24 (5 to 46)
days (Australia). Sites took longer to submit final reports, overall median of 28 (7 to 91) days, ranging from 7 days
(Australia) to 67 (23 to 103) days (Europe).
Conclusions: Population availability and time to ethics and regulatory approvals influence recruitment; therefore
accurate feasibility assessments are critical to site selection. Time to ethics and regulatory approval may not limit
site inclusion if compensated by rapid recruitment. Identifying potential delays and methods for reduction can
decrease time and costs for sponsors.
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Poor site selection in multicentre randomised clinical trials
can result in delayed start-up, unmet target recruitment,
poor data quality and/or research integrity, thereby
contributing to cost inefficiencies in resource and time
allocation. Therefore, tracking a site’s operational per-
formance from a sponsor perspective can identify ways
to improve processes for future studies and to enable
performance comparison between sites.
Use of performance metrics is two-fold: to improve
processes internally (for continuous improvement efforts
and future research), and to strengthen relationships
with sponsors. Benefits for internal operations include:
 Identifying where processes can be improved
 Identifying where resource allocations can change
 Managing the workload effectively across staff
 Establishing performance benchmarks, and
 Providing data-driven rationale to management to
request additional resources.
Benefits from the sponsor relationship perspective
include:
 Identifying areas of strong competitive advantage,
and
 Ability to complete site feasibility questionnaires
with accurate data [1].
Metrics can enable comparison of operational per-
formance between sites [2-5] and their use has been
adopted by sponsors to demand higher levels of metrics-
driven performance [6-10]. Types of metrics include:
 Leading indicators - information that can be acted
on immediately to get the trial back on track
 Lagging indicators - information that can be used
for future trials or for process improvement efforts
 Cycle-time - measures the time taken to complete a
task
 Timeliness - measures whether a particular milestone
was met
 Efficiency - measures the amount of resource
required to complete a task or set of tasks versus
that expected, and
 Quality - measures how well an output from a
process meets the requirements of the customer of
that process [1].
Examples of site performance metrics include:
 Metric #1: Cycle Time from Draft Budget Received
from Sponsor to Budget Finalisation: the time (days)
between the date that the first draft budget isreceived and the date that the sponsor sends
approval of the budget. Long cycle times can signal
the site to identify areas where the process is being
delayed and ways to improve the process. Sites that
have short cycle times for this metric can use the
information to demonstrate their responsiveness to
sponsors [11]
 Metric #2: Cycle Time from Institutional Review
Board (IRB) Submission to IRB Approval: the time
(days) between the dates of initial submission to the
ethics committee and the protocol approval. If the
site is experiencing delays in receiving ethics approval,
process improvement should be investigated between
the site and ethics committee. If the site approves new
trials in a timely fashion, sponsors are more likely to
provide repeat business. Ethics approval is one of the
first milestones in the life cycle of a clinical trial and
the variability between sites at this step is beneficial;
therefore, a good track record for this metric is the
site’s advantage when promoting abilities [11]
 Metric #3: Cycle Time from Full Contract Execution
to Open to Enrolment: the time (days) between the
date of an executed contract and the date subjects
may be enrolled. Recruitment is a significant
challenge across the industry, and as with other
metrics, long cycle times could indicate that the site
should try to identify areas where the process is
being delayed. The metric should be tracked over
time to verify if any changes have had a positive
impact. If the site’s performance for this metric is
good, it should be used to leverage during budget
negotiation. Sites have more time to enrol subjects if
they are able to get protocols open to recruitment
faster. Sites with a history of good performance for
this metric will be selected first for future trials [11]
 Metric #4: Volumetric - Number of Active Protocols:
the number of protocols that are not in long-term
follow-up with one of the following statuses: Open to
Recruitment, Closed to Recruitment, or Suspended
within a given month. This metric determines the
site’s clinical research operations capacity and
efficiency [11]
 Metric #5: Volumetric - Number of New Subject
Recruitments: the number of subjects recruited
during a given month. This metric measures the
site’s ability to deliver on recruitment targets. Sites
with a history of successfully meeting recruitment
targets are selected first for new trials [11].
Recruitment into multicentre, randomised clinical trials
is often slower or more difficult than initially expected,
with many trials failing to reach their planned sample size
within the originally envisaged timeframe and funding
[6,12]. Consequently, trials often require extended
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[6,7,13]. Effective and timely participant recruitment is
therefore essential for the successful completion of a
trial and generation of a valid result, as prolonged or
inefficient recruitment can have adverse scientific,
economic and ethical consequences [6,7,12].
During site selection, sponsors request feasibility infor-
mation on how a site performed on similar studies; that is,
number of enrolled subjects versus what was contracted.
According to the Tufts Centre for the Study of Drug
Development, two thirds of sites do not meet patient
enrolment requirements of a given study [11]. This
metric was used by Winship Cancer Institute at Emory
University to implement positive changes as data
showed that studies that recruit the first patients
slowly are less likely to be successfully completed due
to inadequate overall recruitment. Hence, Winship en-
hanced its closure policies to limit the time and effort
wasted on trials that were unlikely to be successful.
Changes implemented included stricter guidelines related
to recruitment; for example, new trials must reach at least
25% of their target recruitment during the first 6 months
or be subject to closure. After 1 year, the Winship Cancer
Institute was able to demonstrate positive and measurable
changes in the performance of their trials.
There is limited published international, multicentre,
randomised clinical trial data in this area. One study
outlined the use of benchmarking clinical trials con-
ducted in Europe [8], evaluating sites in terms of goals:
 Temporal - number of days to obtain review approvals
to the first subject visit
 Quantity - number of subjects a site can enrol
 Quality - number of queries per case report form
(CRF) [8].
The study concluded that benchmarking provided an
effective tool for improving data quality, reducing time to
market, and declining development costs of international,
multicentre clinical trials. Furthermore, a matrix of per-
formance measures was established to evaluate site
compliance for the South African National Defence
Force-sponsored Project Phidisa [8]. The primary aims
of benchmarking in this setting were to improve data
quality and increase subject safety. Parameters were
evaluated and reported quantitatively, measured against
a target standard. The outcome of the assessment pro-
vided tangible results that were used to target corrective
action in areas needing improvement, not only at the site
level but also within the various sections or departments
that supported the trial.
Operational data can be tracked within a clinical trial
management system (CTMS) or on a spreadsheet; how-
ever the challenge lies in analysing and interpreting thedata in a way that leads to beneficial change. Therefore,
careful consideration is required when setting up a study
to ensure all required operational metrics are defined,
and can be captured appropriately.
The aim of the current exploratory analysis is to
describe regional performance in the Altair study using
operational metrics relating to start-up, recruitment,
data collection, and stored samples, to plan efficient
implementation of future studies.
Methods
Study design of Altair
The Altair study, sponsored by The Kirby Institute,
University of New South Wales, Australia, has been
described previously [14]. Briefly, treatment-naïve HIV-
infected individuals were randomised in equal propor-
tions to receive tenofovir/emtricitabine (TDF 300 mg
once a day (qd)/FTC 200 mg qd) with efavirenz (EFV
600 mg qd) (Arm I), ritonavir-boosted atazanavir (r/
ATV 100 mg/300 mg qd) (Arm II) or zidovudine/abaca-
vir (ZDV 250 mg or 300 mg twice a day (bd)/ABC
600 mg qd) (Arm III). The intention-to-treat (ITT)
population consisted of 322 randomised participants
who received at least 1 dose of study medication and 1
follow-up visit [14].
Thirty-six sites in 15 countries (Argentina, Australia,
Canada, Chile, France, Germany, Hong Kong, Ireland,
Israel, Malaysia, Mexico, Singapore, Taiwan, Thailand,
and United Kingdom) participated in this study. The
sites represented 5 regions including Asia (n = 5 sites),
Australia (n = 10), Europe (including Israel) (n = 7), Latin
America (n = 11), and North America (n = 3). Ethical ap-
proval was received at all sites, although local regulatory
authority approval was not required in Australia, North
America and Israel. Moreover, public hospitals in
Australia, Ireland and United Kingdom underwent
governance evaluation of the protocol. Prior to study
conduct, written informed consent was obtained from
each participant. A list of ethics committees that approved
the Altair study is provided in Appendix.
TDF/FTC was supplied as the fixed-dose combination
(Truvada) to all sites after packaging and labelling of
Gilead clinical trial supply by ALMAC Clinical Services,
Craigavon, Northern Ireland. The drug was not registered
or commercialised at study initiation in Chile, Hong Kong,
Malaysia, Singapore, Taiwan and Thailand.
There were 10 study visits during 96 weeks of follow-up.
The Oracle Electronic Data Capture (EDC) platform
(Oracle, North Ryde, NSW, Australia) was used for data
collection. Data entry was required within 7 days of the
study visit and serious adverse events (SAEs) reported
to the sponsor within 24 hours of site awareness.
Randomised Altair study patients provided informed
consent before permitting storage of plasma and buffy
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buffy coat was collected for DNA isolation with the aim
of conducting future investigations related to HIV
disease. Furthermore, storage of samples for future
genomic testing occurred depending on patient consent.
Samples were shipped to a central facility (St. Vincent’s
Centre for Applied Medical Research, Sydney, Australia)
once the final visit (week 96) was concluded. Paper
inventories were requested at week 48 and prior to
shipping at week 96. The number and quality of samples
were interrogated upon receipt in Sydney and were
compared by region.Statistical analysis
A descriptive analysis of the operational metrics listed
below evaluates regional performance across Asia,
Australia, Europe, Latin America, and North America:
 Start-up:
Time from protocol release to ethics and/or
regulatory submission and approval
Time from protocol release to First Participant
Randomisation (FPR) and Last Participant
Randomisation (LPR)
 Recruitment:
Time from site opening to FPR
Time from FPR to LPR
Actual versus estimated recruitment
 Data collection:
Time from actual visit to EDC initiation
Time from EDC initiation to completion
Number of missing values per participant
Number of queries opened per participant
Number of missed visits per region
Number of SAEs reported0 100 200 300
Asia
Australia
Europe
Latin America
North America
Median days
Regions
Figure 1 Characterisation of start-up ethics and/or regulatory by regiTime from SAE occurrence to initial report
Time from initial SAE report to final report
 Storage samples:
Number of plasma samples collected versus
protocol-mandated samples to be collected
Number of buffy coat samples collected versus
protocol-mandated samples to be collected
Quality of laboratory samples collected
Results
Start-up
Median days from protocol release to site opening was
250 (188 to 266), ranging from 177 (158 to 200)
(Australia) to 265 (205 to 270) (Europe). Figure 1 is a re-
gional characterisation of the median time in days to
submit the protocol to local/regional ethical and/or
regulatory authorities, receive approvals, and randomisation
of the first participant. By region, sites in Australia took the
shortest time to submit and receive ethics approval for the
protocol and randomise the first participant. Recruitment
of the first participant in Europe, Asia, Latin America and
North America took approximately 12 to 14 months from
protocol release.
Recruitment
Figure 2 shows the time from site opening to FPR and
LPR. Following approval, FPR was rapid in Australia,
Latin America and Europe but longer in Asia and North
America. Once the FPR visit was conducted for each
region, sites in Asia, Europe, and North America had
their LPR 2.5 months later. Australia and Latin America
completed recruitment in a minimum of 4 months; the
shortest recruitment period as measured by the time
from site opening to LPR. The recruitment period for
Europe and Asia was 8 months and 9 months for North
America.400 500
First participant randomization
Ethics and/or regulatory
approval
Ethics and/or regulatory
submission
on.
0 100 200 300
Asia
Australia
Europe
Latin America
North America
Median days
Regions Median days from site
opening to FPR
Median days from FPR to
LPR
Figure 2 Recruitment metrics - time from site opening to First Participant Randomisation (FPR) and Last Participant Randomisation
(LPR) by region.
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recruitment and total randomised. The highest enroller
was Latin America, followed by Asia, Europe, Australia
and North America. Actual recruitment was lower than
estimated in Asia, Australia, Europe and North America,
although Latin America (104%) exceeded the estimated
number.
Data collection
Data management
Table 1 demonstrates that EDC was slowest in North
America (median 13 days), followed by Europe. Sites in
Asia, Latin America and Australia started entering data
quickly. All sites completed data entry within 14 days
and sites in Australia had the longest opened queries per
participant (median 2 days), with the other regions
responding to queries on the same or next day.
There were a total of 50 missed visits during the
course of the study. The median number of missed
values per participant was highest in Europe and lowest0
20
40
60
80
100
120
140
Asia Australia Europe
A
Participants
Regions
Figure 3 Actual versus estimated recruitment by region.in Latin America. The remaining three regions had a
similar numbers of missed values per participant.
The median number of queries raised per participant
was lowest in North America; Asia followed closely behind
and the remaining regions reported similar values.
Serious adverse event reporting
There were no SAEs reported in North America
(Table 1). Asia, Australia and Europe reported 2 SAEs
per 10 participants, whilst Latin America only reported
1 per 10 participants. Reporting timelines of the initial
SAE report ranged from 4 to 24 days and 8 to 67 days
for sites to submit the final SAE report.
One unreported SAE was identified in Europe during
a site monitoring visit conducted by the project team.
Storage samples
The expected number of buffy coat and plasma samples
for collection during the study was 30,800. Overall, 82%
of protocol-mandated plasma samples were received atLatin
merica
North
America
Participants estimated for
recruitment
Randomised participants
Table 1 Electronic Data Capture (EDC) and serious adverse event (SAE) reporting
Sites Total
participants
randomised
Mean
participants
randomised
per site
Median number
of queries
opened per
participant
Median number
of missing
values per
participant
Median number
of missed visits
per region
Median days
from actual
visit to EDC
initiation
Median days
from EDC
entry to
completion
SAEs
reported
per 10
participants
Median days
from SAE
occurrence to
initial SAE
report
Median days
from initial
SAE report to
final, accepted
SAE report
Asia 5 101 20 25 22 0 3 9 2 8 37
Australia 10 33 3 35 26 1 5.6 14 2 24 7
Europe 7 64 9 37 53 1 8.7 11 2 5 67
Latin America 11 121 11 34 15 1 5.7 17 1 4 8
North America 3 10 3 21 26 1 13.2 9 0 0 0
Berthon-Jones
et
al.Trials
 (2015) 16:138 
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(North America) (Table 2). The proportion of buffy coat
samples received was 144%, ranging from 110% (Asia) to
179% (Australia). All sites therefore collected additional
buffy coat samples at week 0 that were not required by
the protocol. For all regions except Asia, sites failed to
collect plasma stored samples even though the participant
attended the visit. In Europe, Latin America and Australia,
storage samples were not collected at 7, 5 and 5% of the
visits attended, respectively.
Furthermore, one site sent whole blood and another
four sites sent serum samples that were not on inventories
and were discarded by the central laboratory on arrival
as the samples were not protocol-mandated. Some of the
errors were procedural, where sites consistently collected
the incorrect number or type of samples. These errors
were not identified in the paper inventory until receipt of
samples at the central laboratory.
Discussion
In the current exploratory analysis, we focused on site
performance in terms of speed of start-up, quantity of
recruitment, quality of data and stored samples. Given
the nature of the paper, ethics approval was not
required.
Start-up
The Altair study commenced in March 2007 and was
recruited in 18 months at clinical sites after protocol
release. Prior to this study, the Kirby Institute had 6 years
of conducting similar clinical trials, although had only
previously worked with 50% of the sites participating in
Altair.
Due to the study design and nature of regulatory
guidelines, sites in Australia, Hong Kong and Taiwan did
not require approval from the regulatory authority.
Therefore, delays in start-up were due to receipt of ethics
and governance approval at hospital-based sites, executed
site contracts and indemnities. However, Australia did
not require translated documents, thereby contributing
to the shortest time between site opening and FPR. The
protracted process of obtaining ethics, governance andTable 2 Stored samples mandated by the protocol and receiv
Region Buffy coat samples Pl
Protocol- mandated buffy
coat samples to be collected
Actual buffy coat
samples collected
Pr
pl
be
Asia 203 224 4,5
Australia 66 118 1,4
Europe 130 199 2,8
Latin America 196 317 4,3
North America 20 25 45regulatory approval [15] across countries in Europe
significantly delayed FPR by 13 months from protocol
release. Randomisation of the first participant in Latin
America and Asia was delayed due to establishing site
contracts and import permits for study drugs. Importation
into Latin America is often difficult, with a challenging
clinical trials regulatory environment [16,17] and changing
customs requirements. Study drugs underwent re-labelling
due to a request from the German regulatory authority,
BfARM, delaying delivery to German sites. Obtaining an
adequate level of insurance in countries such as Germany
and Argentina also contributed to ethics approval delays
as sites requested the use of a local insurance provider.
Moreover, it was the first time that we were collaborating
with certain sites in Canada and Europe and contractual
and indemnity negotiations were prolonged from both
directions. Nevertheless, sites in all regions were able to
recruit quickly once open, recruiting patients within an
average of 3 to 4 months. The large number of sites
included contributed to meeting the samples size required
to power the study.
Study documents requiring certified translation included
the protocol, synopsis, participant information and consent
forms, contract, indemnity, insurance certificate, question-
naires related to depression, anxiety and stress and quality
of life. Documents for Asia were translated into Thai,
Bahasa Melayu, Simplified Chinese and Traditional
Chinese. Other translations included French, German,
Hebrew, Russian, Amharic and Spanish for sites in Europe
(including Israel), Latin America and North America.
Document translation contributed to the submission delays
in these regions [18,19] and the first participant was not
randomised until just over a year after the protocol was re-
leased to Latin America, Asia, Europe and North America.
This measure indicates that the feasibility assessment must
capture the required languages to request translation of
study documents as soon as they are finalised and prior to
protocol release. Furthermore, quotes from translation
services using draft study documents should be obtained
during study setup to reduce time delays.
A limitation of this analysis is insufficient data captu-
ring detailed reasons for delayed ethics and governanceed at the central laboratory for testing
asma samples
otocol- mandated
asma samples to
collected
Actual plasma
samples collected
Proportion of visits where
plasma samples were not
collected as required (%)
45 3,582 0
85 1,314 5
80 2,293 7
65 3,607 5
0 444 1
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submission could be due to late receipt of translated
documents from the sponsor, prolonged review of site-
specific documents by the sponsor, ability of the site to
prepare a high-quality submission package, availability
of department heads to obtain signatures on documents,
and the study coordinator’s current workload (that is if
there are many recruiting studies, then studies in start-
up are not prioritised). In addition to the difficulty
posed when establishing site contracts that require
translation, delayed governance submissions could also
be due to prolonged budget negotiations between
the site and the sponsor, and can indicate that the
proposed budget is insufficient for a site to cover
costs. Therefore, during feasibility and site selection,
it would be useful to obtain a site’s standard setup
costs including:
 Start-up fees for the site, pharmacy and laboratory
 Archiving and close out
 Lead site fees for additional administration
 Ethics and governance review fees for the main
study and substudies
 Pharmacy fees for dispensing, destruction, call back,
drug transfers
 Institutional overhead
Sites that are yet to develop a schedule of fees for
clinical trial services should consider the above factors
and conduct a time and motion study for participant
visit-related procedures; for example, time taken to
conduct informed consent, assess eligibility criteria,
medical history and conduct physical examination by
the principal investigator (PI).
Recruitment
Recruitment was lower than pre-study estimations by
sites in Asia, Australia, Europe, and North America due
to a lower naïve patient population in the latter three re-
gions and a competing naïve study in Australia. Despite
multiple delays during start-up, recruitment in Latin
America exceeded the estimated total within a 3-month
period.
This metric demonstrates the importance of accurate
data when sites are completing feasibility questionnaires.
In order to estimate the recruitment target and the
intended recruitment period, sites should be asked to
provide the total number of active protocols, number of
active protocols per study coordinator (SC), number of
new subject recruitment and screen failures during a
given month, number of previous similar studies and re-
spective recruitment, and number of competing studies.
Knowing how much time SCs spend on various study-
related tasks is extremely useful and beneficial from bothsite and sponsor perspectives. It demonstrates where
there may be inefficiencies and room for process
improvement, allows improved planning, and enables
accurate budgeting for the time and effort required to
conduct a study. Documenting work effort requires
staff to log their time, whether in a spreadsheet, a
CTMS, or other system. With complete and up-to-date
logs filled out, sites can view a detailed report of staff
time across activities and protocols. Therefore, a site
should invest in calculating an average full-time
equivalent allocation to ensure staff is neither overbur-
dened nor under-utilised.
Other factors that may impact recruitment at a site may
include the process of identifying suitable participants
(for example, patient database and referrals) and methods
of effective advertising.
Following this analysis, the Kirby Institute imple-
mented a more rigorous feasibility questionnaire to be
completed during site selection for future studies.
Data collection
Only ten participants were randomised in North America
although initial data entry following the visit was delayed
by a week. In contrast, sites in Asia and Latin America
that randomised over 100 participants began data entry
within a week after the visit. The number of missing
values per participant varied largely from 15 in Latin
America to 53 in Europe; however, the number of queries
opened per participant remained fairly consistent across
regions. The rate of missed visits was very low across all
regions.
The majority of the reported SAEs (83%) were hospita-
lisations, hence extending the reporting timelines be-
tween the initial and final reports. There were no SAEs
reported from the North American region and most
(63%) were from Latin America and Asia, corresponding
to the proportion of global recruitment. A total of 63%
of the SAEs reported from Thailand were hospitalisa-
tions reflecting the current environment for receiving
medical treatment covered by health insurance. Strict
confidentiality and privacy laws surrounding access to
medical records from local hospitals also influenced
timelines for completing follow-up SAE reports from
this region.
Prolonged data entry, a high number of missing values
and missed visits indicate that site staff may require ad-
ditional protocol and data entry training. Moreover, the
SC’s current workload may also be represented within
these measures; that is if the workload is high, there is
less time to focus on data quality.
The Kirby Institute implemented weekly remote
monitoring of data entry for all future studies to ensure
improved data quality and integrity.
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Clinical trials of immunologic therapies provide oppor-
tunities to study the cellular and molecular effects of
those therapies and may permit identification of bio-
markers of response. When the trials are performed at
multiple centres, transport and storage of clinical speci-
mens become important variables that may affect blood
and tissue specimens [20,21]. There were many errors
resulting from shipment at trial completion in the Altair
study, highlighting the need for better laboratory oversight
by site staff.
Over-collection of buffy coat samples and under-
collection of plasma samples identified a need for
additional laboratory training during the lifetime of the
study; however, as paper inventories were utilised to
document sample collection and shipments to the cen-
tral laboratory occurred at study closure, the sponsor
was not alerted to this problem in real-time. Further-
more, the extra buffy coat samples resulted in additional
shipping costs borne by the sponsor, and the smaller
quantity of plasma ensured fewer samples to conduct
future investigations in HIV disease.
The outcome from this analysis proved a need to im-
prove stored sample processes for future studies using
several strategies such as improving communication
with local laboratory staff, increasing the number and
quality of laboratory monitoring visits and greater
frequency of shipping to the central laboratory (even if
incurring more expense). As a result of the Altair study
sample shipments, The Kirby Institute studies now employ
an electronic inventory to allow real-time monitoring of
the type and number of samples collected by sites. This
has allowed early identification and resolution of errors
prior to shipment.
Conclusions
The proposed strategy for comparing performance of
service providers in clinical trials was intended to help
interpret differences due to factors affecting start-up,
recruitment, data and storage sample collection across
regions. It was hoped to provide metrics to establish
compliance for future studies in order to meet required
timelines and improve cost-efficiency.
Multicentre randomised clinical trials that have been
conducted since the Altair study have focused attention
on site selection strategies tailored specifically to address
the target population required for the protocol, as well
as attention to recruitment, data and stored sample col-
lection. The site selection process itself is dependent on
multiple factors in addition to the quantity of suitable
and available participants at the site and PIs are en-
couraged to be realistic in their recruitment forecasts.
In an attempt to reduce cost and time inefficiency,
some studies implemented a cut-off on recruitmentestimated by sites and others targeted sites that have a
good track record in conducting large, randomised
clinical trials with known PIs. The Kirby studies also
commenced tracking of recruitment more closely, and
maintained frequent communication with site PIs and
SCs to identify ways to improve recruitment. Remote
monitoring of data collected occurred weekly to ensure
data entry was timely, missing values were not a recurring
problem, and any missed visits were followed up with the
site to confirm the reason. Stored samples are being
tracked via an electronic inventory to ensure the correct
number and type of samples are being collected.
It was apparent with the Altair study that certain re-
gions are more worthwhile than others in terms of cost
efficiency and timeliness of recruitment. For example,
sites in Asia and Latin America took longer than sites in
Australia to commence enrolment, however participant
recruitment and data quality in these regions compensated
for the initial delays. Moreover, sites in Asia excelled in
data quality and storage sample collection relative to other
regions.
Appendix
List of ethics committees that approved the Altair study
 CAICI, Argentina
 Hospital Central, Argentina
 FUNDAI, Argentina
 Hospital Alvarez, Argentina
 Hospital Alende, Argentina
 Hospital Italiano, Argentina
 Hospital Ramos Mejia, Argentina
 Hospital Posadas, Argentina
 Hospital Rawson, Argentina
 The Alfred, Australia
 St Vincent’s Hospital, Australia
 Sydney South West Area Heath Service, Australia
 The Royal Melbourne Hospital, Australia
 Westmead Hospital, Australia
 Royal Perth Hospital, Australia
 St George Hospital, Australia
 University of Calgary, Canada
 Toronto General Hospital, Canada
 Fundacian Arriaran, Chile
 Hospital Saint-Louis, France
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